Literature DB >> 35005525

Origin and evolutionary analysis of the SARS-CoV-2 Omicron variant.

Yamin Sun1,2, Wenchao Lin2, Wei Dong2, Jianguo Xu1,3.   

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has evolved rapidly into new variants throughout the pandemic. The Omicron variant has more than 50 mutations when compared with the original wild-type strain and has been identified globally in numerous countries. In this report, we analyzed the mutational profiles of several variants, including the per-site mutation rate, to determine evolutionary relationships. The Omicron variant was found to have a unique mutation profile when compared with that of other SARS-CoV-2 variants, containing mutations that are rare in clinical samples. Moreover, the presence of five mouse-adapted mutation sites suggests that Omicron may have evolved in a mouse host. Mutations in the Omicron receptor-binding domain (RBD) region, in particular, have potential implications for the ongoing pandemic.
© 2021 Published by Elsevier B.V. on behalf of KeAi Communications Co., Ltd.

Entities:  

Keywords:  Mouse-adapted mutation; Omicron variant; Reverse zoonosis; SARS-CoV-2

Year:  2021        PMID: 35005525      PMCID: PMC8718870          DOI: 10.1016/j.jobb.2021.12.001

Source DB:  PubMed          Journal:  J Biosaf Biosecur        ISSN: 2588-9338


Introduction

The current COVID-19 pandemic is a global human health crisis caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). On 26 November 2021, the World Health Organization (WHO) designated the SARS-CoV-2 variant B.1.1.529, named Omicron, as its fifth variant of concern (VOC). This decision was based on the evidence presented to health officials and researchers that Omicron had numerous mutations with potential implications for the ongoing pandemic. The Omicron variant has now been identified globally, including countries throughout Asia, Africa, Europe, and North America. The original wild-type SARS-CoV-2 strain likely originated in a bat host.2, 3, 4 Initially, pangolins were thought to be the source of spillover to humans, but they may have been infected by other animal species. Since the outbreak of COVID-19, several countries have reported infections of SARS-CoV-2 in animals. Human-to-animal transmission has been observed in pets, farmed animals, and animals held in zoos, in addition to free-ranging wild animals.6, 7 For example, infections under natural conditions have been reported in pet dogs and cats, in farmed mink and ferrets, and tigers, lions, snow leopards, pumas, and gorillas at zoos. Most diseased animals are hypothesized to have been infected through close contact with COVID-19-positive human patients. However, no compelling evidence currently shows that any domestic animal can readily transmit SARS-CoV-2 to other animals, including humans. Few animal cases have shown the potential for further zoonotic and anthroponotic viral transmission. Nevertheless, infection in domestic and wild animal species has possible implications for public health. SARS-CoV-2 enters host cells via the interaction of spike-like proteins (S proteins) on the viral surface with the host cell entry receptor angiotensin-converting enzyme 2 (ACE2). Some variants that have mutations in the receptor-binding domain (RBD) region of the S protein are VOC because they are potentially associated with enhanced transmission, pathogenicity, and/or immune evasion. Although the initial wild-type strain of SARS-CoV-2 does not infect mice, mouse-adapted SARS-CoV-2 strains have been identified. Several mouse-adapted strains have mutations located in the RBD region, enhancing interactive affinities with mouse ACE2 (mACE2) to facilitate efficient viral replication in this host. A mouse-adapted strain at passage 6 (MASCp6), which has an N501Y mutation, was shown to have increased infectivity in the lung during serial passaging in BALB/c mice. Another study showed that three SARS-CoV-2 VOCs, namely B.1.1.7 and two other N501Y-carrying variants, B.1.351 and P.3, can infect mice. In this study, we constructed a phylogenetic tree of all known VOCs and variants of interest (VOIs). The results showed that the Omicron variant was not present on an intermediate evolutionary branch, suggesting that it may have evolved in a non-human host. Analysis of Omicron mutation data revealed a high number of mutations, that these mutations are concentrated in the S protein (specifically the RDB region), and that Omicron has five mouse-adapted mutation sites. Together, the data suggest that Omicron may have evolved in a mouse host.

Materials and methods

Data collection

We downloaded a representative set of SARS-CoV-2 genomes from individuals infected during the COVID-19 pandemic from the GISAID database. The genomes had complete metadata, including patient age and sex and the year and country in which samples were collected. These data were used to test associations between variation in SARS-CoV-2 genomes and available epidemiological metadata.

Mutation analysis

The complete genome of SARS-CoV-2 isolate Wuhan-Hu-1 (NC_045512.2) was used as the reference genome, and mutations in all other samples were compared with this reference isolate. Detected mutations were confirmed with Integrative Genomics Viewer (IGV) and annotated with the SnpEff program.

Construction of a phylogenetic tree with full-length genomic sequences

The full-length genomic sequences of VOCs and VOIs used in this analysis included 30 each of the Alpha, Beta, Eta, Iota, Mu, Kappa, Zeta, Theta, Epsilon, and Omicron variants. There were also 28 Gamma, 98 Delta, and 29 Lambda variant genomes included. All 455 genomes were aligned using MAFFT v7.31023. The aligned sequences were converted to the phylip file format with Clustal W, and maximum likelihood (ML) trees were then constructed in RaxML v8.2.12 with 100 bootstrap replicates. The time-scaled phylogenetic trees were constructed using NextStrain and Treetime and visualized with FigTree v1.4.4.

Results and discussion

High number of mutations

We calculated the average number of mutations in the five VOCs circulating globally and found that the Omicron variant has significantly more mutations than any other variant currently in circulation (Table 1 ). This observation suggests that the environment in which Omicron evolved may differ from other known VOCs that have infected healthy human hosts. The Omicron variant likely evolved in an immunocompromised patient, although it is possible that this variant also evolved in an animal host.
Table 1

The average number of mutations per sample in each VOC is based on publicly available datasets.

VariantAverage number of mutations
Alpha29.7
Gamma29.1
Beta28.4
Delta35.4
Omicron53.3
The average number of mutations per sample in each VOC is based on publicly available datasets.

Key mutation positions

The RBD region recognizes ACE2, the host receptor that binds to the viral S protein. Mutations in the RBD region may increase the binding affinity and viral infectivity. Furthermore, most vaccine-induced neutralizing antibodies and antibody treatments target the RBD. The Omicron variant has at least 15 mutations in the RBD region, including mutations at Q493 and Q498 (Fig. 1 ), which are especially concerning to public health experts. Studies have shown that mutations at these two sites are related to the infectivity of animals. In 2021, the Jin research team showed that strains with the Q493K and Q498H mutations have significantly enhanced affinity toward mACE2. In a study of New York sewer samples published in July 2021, researchers found many variants with the Q493K and Q498Y mutations, which were rare in clinical samples. At that time, only three reported strains of SARS-CoV-2 had the Q498H mutation, and none had the Q498Y mutation. This study showed that by July 2021, the Q498 mutation had accumulated in large numbers of animal hosts living in the sewers of New York, and the authors discussed the possibility of SARS-CoV-2 spreading between non-human animal hosts. A CSIRO study additionally identified seven key mutation sites potentially related to mACE2 binding affinity. In the S protein, these sites are K417, E484, F486, Q493, Q498, P499, and N501.28, 29, 30, 31 We compared key mutations in 13 mouse-adapted strains with the Omicron variant (Fig. 2 ). The results showed that the Omicron variant contains mutations at five key sites of viral S protein: K417, E484, Q493, Q498, and N501. Notably, another strain had mutations at the same five sites, the IA-501Y-MA-30 strain, which was obtained from mouse lung samples after 30 passages of the IA-501Y strain. These results suggest that the Omicron variant may have evolved in a mouse host.
Fig. 1

Mutation profiles of the five variants of concern (VOCs) designated by the World Health Organization. Common mutations are marked in red. Many mutations in the Omicron variant are unique when compared with mutations in other VOCs.

Fig. 2

Seven key mutations among 13 mouse-adapted strains and the Omicron variant of SARS-CoV-2. IA-501Y-MA-30 is a homogenate obtained from mouse lung after 30 passages of the IA-501Y strain.

Mutation profiles of the five variants of concern (VOCs) designated by the World Health Organization. Common mutations are marked in red. Many mutations in the Omicron variant are unique when compared with mutations in other VOCs. Seven key mutations among 13 mouse-adapted strains and the Omicron variant of SARS-CoV-2. IA-501Y-MA-30 is a homogenate obtained from mouse lung after 30 passages of the IA-501Y strain.

Phylogenetic analysis of VOCs and VOIs

Despite a large number of mutations in Omicron, no evidence was found in known public databases to suggest that these mutations slowly accumulated over time. Additionally, phylogenetic trees showed no intermediate branches of evolution, which is a very surprising result. Starting in August 2021, the Delta variant was dominant globally, and until November 2021, 99.6% of all collected specimens causing new infections were identified as Delta (Fig. 3 A). If Omicron evolved from a strain of the Delta variant, such as AY.4, AY.23, or AY.46 (the dominant variants in Europe, Asia, and Africa, respectively), they would share a common mutation profile. However, analysis of data from GISAID showed that the Omicron variant differed from each of these strains and did not evolve from the Delta variant (Fig. 3B). The phylogenetic analysis strongly indicates that the Omicron variant forms a monophyletic group with the Gamma variant as a sister group, and the Omicron group has an extremely long branch length. The time-scaled phylogenetic tree shows that the Omicron and Gamma lineages likely diverged in the first half of 2020. This supports the hypothesis that Omicron may have evolved in a non-human animal species. After accumulating many mutations in the animal host, the altered coronavirus was transmitted back to humans by reverse zoonosis.
Fig. 3

The abundance of different SARS-Cov-2 variants by percent of new infections from a public database (A). Evolutionary analysis shows that the Omicron variant did not evolve from the Delta variant and differs from other variants (B).

The abundance of different SARS-Cov-2 variants by percent of new infections from a public database (A). Evolutionary analysis shows that the Omicron variant did not evolve from the Delta variant and differs from other variants (B). The emergence of the Omicron variant indicates that surveillance of SARS-CoV-2 variants should be conducted in economically underdeveloped countries and in the environment to avoid the continuous emergence of new variants of unknown origin. Understanding the threat posed by the Omicron variant will require researchers to gather and analyze a great deal more data in a brief period. Determining the origin of Omicron requires surveillance of animals, especially rodents, because they may have come into contact with humans carrying a strain of the virus with adaptive mutations. Future work should focus on SARS-CoV-2 variants isolated from other wild animals to investigate the evolutionary trajectories and biological properties of these variants both in vitro and in vivo. If Omicron is determined to have been derived from animals, the implications of it circulating among non-human hosts will pose new challenges in the prevention and control of the epidemic.

CRediT authorship contribution statement

Yamin Sun: Writing – original draft, Visualization. Wenchao Lin: Writing – original draft. Wei Dong: Software, Data curation. Jianguo Xu: Supervision, Writing – review & editing. Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
  29 in total

1.  Monitoring of SARS-CoV-2 infection in mustelids.

Authors:  Anette Boklund; Christian Gortázar; Paolo Pasquali; Helen Roberts; Søren Saxmose Nielsen; Karl Stahl; Arjan Stegeman; Francesca Baldinelli; Alessandro Broglia; Yves Van Der Stede; Cornelia Adlhoch; Erik Alm; Angeliki Melidou; Grazina Mirinaviciute
Journal:  EFSA J       Date:  2021-03-03

2.  CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice.

Authors:  J D Thompson; D G Higgins; T J Gibson
Journal:  Nucleic Acids Res       Date:  1994-11-11       Impact factor: 16.971

3.  Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor.

Authors:  Jun Lan; Jiwan Ge; Jinfang Yu; Sisi Shan; Huan Zhou; Shilong Fan; Qi Zhang; Xuanling Shi; Qisheng Wang; Linqi Zhang; Xinquan Wang
Journal:  Nature       Date:  2020-03-30       Impact factor: 49.962

4.  RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies.

Authors:  Alexandros Stamatakis
Journal:  Bioinformatics       Date:  2014-01-21       Impact factor: 6.937

5.  A pneumonia outbreak associated with a new coronavirus of probable bat origin.

Authors:  Peng Zhou; Xing-Lou Yang; Xian-Guang Wang; Ben Hu; Lei Zhang; Wei Zhang; Hao-Rui Si; Yan Zhu; Bei Li; Chao-Lin Huang; Hui-Dong Chen; Jing Chen; Yun Luo; Hua Guo; Ren-Di Jiang; Mei-Qin Liu; Ying Chen; Xu-Rui Shen; Xi Wang; Xiao-Shuang Zheng; Kai Zhao; Quan-Jiao Chen; Fei Deng; Lin-Lin Liu; Bing Yan; Fa-Xian Zhan; Yan-Yi Wang; Geng-Fu Xiao; Zheng-Li Shi
Journal:  Nature       Date:  2020-02-03       Impact factor: 69.504

6.  Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding.

Authors:  Roujian Lu; Xiang Zhao; Juan Li; Peihua Niu; Bo Yang; Honglong Wu; Wenling Wang; Hao Song; Baoying Huang; Na Zhu; Yuhai Bi; Xuejun Ma; Faxian Zhan; Liang Wang; Tao Hu; Hong Zhou; Zhenhong Hu; Weimin Zhou; Li Zhao; Jing Chen; Yao Meng; Ji Wang; Yang Lin; Jianying Yuan; Zhihao Xie; Jinmin Ma; William J Liu; Dayan Wang; Wenbo Xu; Edward C Holmes; George F Gao; Guizhen Wu; Weijun Chen; Weifeng Shi; Wenjie Tan
Journal:  Lancet       Date:  2020-01-30       Impact factor: 79.321

7.  A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures.

Authors:  Kenneth H Dinnon; Sarah R Leist; Alexandra Schäfer; Caitlin E Edwards; David R Martinez; Stephanie A Montgomery; Ande West; Boyd L Yount; Yixuan J Hou; Lily E Adams; Kendra L Gully; Ariane J Brown; Emily Huang; Matthew D Bryant; Ingrid C Choong; Jeffrey S Glenn; Lisa E Gralinski; Timothy P Sheahan; Ralph S Baric
Journal:  Nature       Date:  2020-08-27       Impact factor: 49.962

8.  SARS-CoV-2 infection in domestic and feral cats: Current evidence and implications.

Authors:  Khan Sharun; AbdulRahman A Saied; Ruchi Tiwari; Kuldeep Dhama
Journal:  Vet Q       Date:  2021-07-28       Impact factor: 3.320

9.  Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic.

Authors:  Salim S Abdool Karim; Quarraisha Abdool Karim
Journal:  Lancet       Date:  2021-12-03       Impact factor: 202.731

10.  Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy.

Authors:  Hongjing Gu; Qi Chen; Guan Yang; Lei He; Hang Fan; Yong-Qiang Deng; Shibo Jiang; Shihui Sun; Cheng-Feng Qin; Yusen Zhou; Yanxiao Wang; Yue Teng; Zhongpeng Zhao; Yujun Cui; Yuchang Li; Xiao-Feng Li; Jiangfan Li; Na-Na Zhang; Xiaolan Yang; Shaolong Chen; Yan Guo; Guangyu Zhao; Xiliang Wang; De-Yan Luo; Hui Wang; Xiao Yang; Yan Li; Gencheng Han; Yuxian He; Xiaojun Zhou; Shusheng Geng; Xiaoli Sheng
Journal:  Science       Date:  2020-07-30       Impact factor: 47.728

View more
  23 in total

Review 1.  Characteristics and management of SARS-CoV-2 delta variant-induced COVID-19 infections from May to October 2021 in China: post-vaccination infection cases.

Authors:  Boqi Xiang; Yunhua Zhang; Qiong Ling; Zhenrong Xie; Na Li; Duozhi Wu
Journal:  Am J Transl Res       Date:  2022-06-15       Impact factor: 3.940

Review 2.  Surveillance of omicron variants through wastewater epidemiology: Latest developments in environmental monitoring of pandemic.

Authors:  Vatika Soni; Shilpa Paital; Pankaj Raizada; Tansir Ahamad; Aftab Aslam Parwaz Khan; Sourbh Thakur; Pardeep Singh; Chaudhery Mustansar Hussain; Swati Sharma; Ashok Kumar Nadda
Journal:  Sci Total Environ       Date:  2022-06-15       Impact factor: 10.753

3.  Structural and biochemical mechanism for increased infectivity and immune evasion of Omicron BA.2 variant compared to BA.1 and their possible mouse origins.

Authors:  Youwei Xu; Canrong Wu; Xiaodan Cao; Chunyin Gu; Heng Liu; Mengting Jiang; Xiaoxi Wang; Qingning Yuan; Kai Wu; Jia Liu; Deyi Wang; Xianqing He; Xueping Wang; Su-Jun Deng; H Eric Xu; Wanchao Yin
Journal:  Cell Res       Date:  2022-05-31       Impact factor: 46.297

Review 4.  Cats and SARS-CoV-2: A Scoping Review.

Authors:  Ramona Doliff; Pim Martens
Journal:  Animals (Basel)       Date:  2022-05-30       Impact factor: 3.231

Review 5.  Omicron variant infection and the associated immunological scenario.

Authors:  Anirban Goutam Mukherjee; Uddesh Ramesh Wanjari; Reshma Murali; Uma Chaudhary; Kaviyarasi Renu; Harishkumar Madhyastha; Mahalaxmi Iyer; Balachandar Vellingiri; Abilash Valsala Gopalakrishnan
Journal:  Immunobiology       Date:  2022-05-04       Impact factor: 3.152

6.  Vaccine breakthrough infections with SARS-CoV-2 Alpha mirror mutations in Delta Plus, Iota, and Omicron.

Authors:  Brenda Martínez-González; Lucía Vázquez-Sirvent; María E Soria; Pablo Mínguez; Llanos Salar-Vidal; Carlos García-Crespo; Isabel Gallego; Ana I de Ávila; Carlos Llorens; Beatriz Soriano; Ricardo Ramos-Ruiz; Jaime Esteban; Ricardo Fernandez-Roblas; Ignacio Gadea; Carmen Ayuso; Javier Ruíz-Hornillos; Concepción Pérez-Jorge; Esteban Domingo; Celia Perales
Journal:  J Clin Invest       Date:  2022-05-02       Impact factor: 19.456

Review 7.  Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic.

Authors:  Rekha Khandia; Shailja Singhal; Taha Alqahtani; Mohammad Amjad Kamal; Nahed A El-Shall; Firzan Nainu; Perumal Arumugam Desingu; Kuldeep Dhama
Journal:  Environ Res       Date:  2022-01-29       Impact factor: 8.431

8.  Molecular SARS-CoV-2 surveillance in Bavaria shows no Omicron transmission before the end of November 2021.

Authors:  Jennifer Flechsler; Ute Eberle; Alexandra Dangel; Nikolaus Ackermann; Andreas Sing; Sabrina Hepner; Clara Wimmer; Johannes Lutmayr; Regina Konrad; Carola Berger; Laura Weise; Annika Sprenger; Jörg Zeitler; Natali Paravinja; Hildegard Angermeier; George Githure; Sandra Schmidt; Bianca Treis; Mercy Okeyo; Bernhard Liebl
Journal:  Infection       Date:  2022-03-01       Impact factor: 7.455

Review 9.  "Is Omicron mild"? Testing this narrative with the mutational landscape of its three lineages and response to existing vaccines and therapeutic antibodies.

Authors:  Vijay Rani Rajpal; Shashi Sharma; Avinash Kumar; Shweta Chand; Lata Joshi; Atika Chandra; Sadhna Babbar; Shailendra Goel; Soom Nath Raina; Behrouz Shiran
Journal:  J Med Virol       Date:  2022-04-27       Impact factor: 20.693

Review 10.  Mutations and Evolution of the SARS-CoV-2 Spike Protein.

Authors:  Nicholas Magazine; Tianyi Zhang; Yingying Wu; Michael C McGee; Gianluca Veggiani; Weishan Huang
Journal:  Viruses       Date:  2022-03-19       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.